Re: Seeking Alpha: Evaluating The Upcoming Opportunities
I jst read the article rather carefully...but I didn't see any reference to Europe...missed it?
He assumes all three ongoing label expansion trials will succeed...I hope that becomes reality.
He assumes very conservative market shares for each of the new labels...that;s good.
His price projections bring a sense of euphoria to me...potentially $398 by 2024 !!! and way beyond by 2030.
IF, any Pharma company has the same analysis as the author does. HOW IN THE WORLD does ACAD stay independent at these current prices. IF his projections are within 50% accuracy, I'd be very disappointed with a buyout today at $100/share.
There is a time to under promise and over deliver, and there is a time to defend the stock. Davies and BB know this well. When we begin to see an aggressive defense os the share price, THEN we all know what they know, and that is imminent success with FDA.